PropeciaŽ (also known by its active ingredient Finasteride) was approved by the FDA in 1997 as a treatment for male pattern hair loss. PropeciaŽ prevents the conversion of testosterone to dihydrotestoterone (DHT) in the body, which has been implicated in the balding process. This litigation involves actions seeking damages and/or other relief arising allegedly from the use of PropeciaŽ.

Privacy Policy | Contact Us | © New Jersey Judiciary